



Vicore announces the Nomination Committee for the 2022 Annual General Meeting

Gothenburg, October 20, 2021 – Vicore Pharma Holding AB (publ) has appointed the Nomination Committee for the 2022 Annual General Meeting. The three largest shareholders as of August 31, 2021 have been offered to appoint a member to the Nomination Committee each, in accordance with the decision taken at the Annual General Meeting on May 11, 2021.

The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Ulrik Grönvall appointed by Swedbank Robur and Jannis Kitsakis, appointed by Fourth Swedish National Pension Fund. Vicore Pharma's chairman, Michael Wolff Jensen, is also a member and acts as the convener of the Nomination Committee.

The task of the Nomination Committee is to prepare and present proposals for the number of Board members to be elected by the AGM, the election of a Chairman and other members of the Board, board fees and, if any, remuneration for committee work, election of a Chairman to the Annual General Meeting, election of auditors (if applicable) and auditors fees (if applicable) and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2023.

The Annual General Meeting of Vicore Pharma Holding AB (publ) will take place on May 11, 2022. Shareholders who wish to submit their comments or submit proposals to the Nomination Committee may do so by March 11, 2022, by email to info@vicorepharma.com or by letter to Vicore Pharma Holding AB (publ), Kronhusgatan 11, 411 05 Gothenburg. The Nomination Committee's proposal will be presented in the notice convening the AGM and on the company's website.

For further information, please contact:

Michael Wolff Jensen, Chairman of the Board, tel: +45 227 405 05

michael.wolff-jensen@vicorepharma.com

This information was submitted for publication on October 20, 2021 at 09:00 CET.

About Vicore Pharma Holding AB (publ)

Vicore is a rare disease pharmaceutical company focused on fibrotic lung disease and related indications. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. VP03 includes the development of new AT2 receptor agonists. VP04 develops a clinically validated digital therapeutic for IPF patients.

The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.